Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

111.67 -4.96 (-4.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
What Analysts Are Saying About Axsome Therapeutics Stock
Via Benzinga
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential. 
Via InvestorPlace
3 Biotech Stocks to Buy and Hold for the Next 10 Years
There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon. 
Via The Motley Fool
Axsome Therapeutics (AXSM) Q4 2023 Earnings Call Transcript
AXSM earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Earnings Outlook For Axsome Therapeutics
Via Benzinga
The Latest Analyst Ratings For Axsome Therapeutics
Via Benzinga
The Analyst Landscape: 6 Takes On Axsome Therapeutics
Via Benzinga
Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones
Axsome Therapeutics Q4 2023 revenues surge to $71.53 million, Auvelity sales hit $130.1 million for the year. Sunosi sees 67% YoY growth. 
Via Benzinga
Axsome Tumbles On An Unexpected Setback For Its Alzheimer's Drug
The company is testing a treatment for patients with agitation due to Alzheimer's disease. 
Via Investor's Business Daily
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
2 Stocks That Could Double Your Money in 5 Years
These market-beating stocks could be just getting started. 
Via The Motley Fool
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy. 
Via Benzinga
Earnings Scheduled For February 20, 2024
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion. 
Via Benzinga
5 medical stocks growing earnings by triple digits
There is a little known way to pick stocks like the pros do, and today's exercise points you to five high-probability winners in a sector that's quickly turning 
Via MarketBeat
Topics Economy
Exposures Economy
Cramer Praises Asset Manager's 'Amazing Quarter,' But As For SolarEdge? 'Too Hard To Own'
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying BlackRock, Inc. (NYSE: BLK). 
Via Benzinga
Axsome Depression Drug's Commercial Success, Pipeline Potential Undervalued, Analyst Says
Axsome Therapeutics' growth potential with RBC Capital's optimistic coverage. Auvelity's rapid Rx growth projects sales of $296M in 2024, outperforming estimates. 
Via Benzinga
Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
From Axsome Therapeutics, Inc.
Via GlobeNewswire
3 Stocks That Have Turned $50,000 Into More Than $500,000 in Just 5 Years
Is it too late to invest in these fast-growing stocks? 
Via The Motley Fool
2 Biotech Stocks You Can Buy and Hold for the Next Decade
The types of innovative drugs these companies develop are always in high demand. 
Via The Motley Fool
Prediction: These 3 Stocks Will Soar in 2024
Investors could enjoy an especially happy new year with these great stocks. 
Via The Motley Fool
Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
3 Unstoppable Stocks to Buy Right Now
These stocks could be just the ticket for investors seeking strong growth. 
Via The Motley Fool
Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today
From Axsome Therapeutics, Inc.
Via GlobeNewswire
AXSM DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
From The Rosen Law Firm PA
Via GlobeNewswire
AXSM FINAL DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM
WHY: NEW YORK, NY - (NewMediaWire) - November 25, 2023 - Rosen Law Firm, a global investor rights law firm, reminds investors of the common stock of Axsome Therapeutics, Inc. (“Axsome”) (NASDAQ: AXSM)... 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
AXSM FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
From The Rosen Law Firm PA
Via GlobeNewswire
Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7
From Axsome Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.